Non-interventional LUME-BioNIS study of nintedanib plus docetaxel after chemotherapy in adenocarcinoma non-small cell lung cancer: A subgroup analysis in patients with prior immunotherapy-Reference-Cited by-同舟云学术

Non-interventional LUME-BioNIS study of nintedanib plus docetaxel after chemotherapy in adenocarcinoma non-small cell lung cancer: A subgroup analysis in patients with prior immunotherapy

Published:2020-10 Issue: Volume:148 Page:159-165
ISSN:0169-5002
Container-title:Lung Cancer
language:en
Short-container-title:Lung Cancer

Author:

Reck Martin,Syrigos Kostas,Miliauskas Skaidrius,Zöchbauer-Müller Sabine,Fischer Jürgen R.,Buchner Hannes,Kitzing Thomas,Kaiser Rolf,Radonjic Dejan,Kerr Keith

Funder

Boehringer Ingelheim

Publisher

Elsevier BV

Subject

Cancer Research,Pulmonary and Respiratory Medicine,Oncology

Reference33 articles.

1. Vargatef® Summary of Product Characteristics. https://www.ema.europa.eu/en/documents/product-information/vargatef-epar-product-information_en.pdf (Accessed: 20 December 2019).

2. Triple angiokinase inhibitor nintedanib directly inhibits tumor cell growth and induces tumor shrinkage via blocking oncogenic receptor tyrosine kinases;Hilberg;J. Pharmacol. Exp. Ther.,2018

3. Docetaxel plus nintedanib versus docetaxel plus placebo in patients with previously treated non-small-cell lung cancer (LUME-Lung 1): a phase 3, double-blind, randomised controlled trial;Reck;Lancet Oncol.,2014

4. Immune checkpoint inhibitors in non-small cell lung cancer;Herzberg;Oncologist,2017

5. Metastatic non-small cell lung cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up;Planchard;Ann. Oncol.,2018

Cited by 17 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Simultaneously Inhibiting P-gp Efflux and Drug Recrystallization Enhanced the Oral Bioavailability of Nintedanib;Current Pharmaceutical Biotechnology;2023-12

2. Safety and tolerability of weekly docetaxel plus nintedanib: A phase I trial after first-line chemotherapy failure in NSCLC;PLOS ONE;2023-10-17

3. Anti-angiogenic agents for NSCLC following first-line immunotherapy: Rationale, recent updates, and future perspectives;Lung Cancer;2023-05

4. Controversies in NSCLC: which second-line strategy after chemo-immunotherapy?;ESMO Open;2023-04

5. Nintedanib in an elderly non-small-cell lung cancer patient with severe steroid-refractory checkpoint inhibitor-related pneumonitis: A case report and literature review;Frontiers in Immunology;2023-01-10